Yen Yung-Chang, Lin Charlene, Lin Shih-Wei, Lin Yung-Song, Weng Shih-Feng
Department of Ophthalmology, Chi Mei Medical Centre, Liou-Ying, Tainan City, Taiwan.
Department of Molecular and Cell Biology, University of California, Berkeley, California.
Head Neck. 2015 Sep;37(9):1268-73. doi: 10.1002/hed.23743. Epub 2014 Jul 11.
The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes.
We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met(+) ) and half were not (Met(-) : controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined.
The incidence of head and neck cancer was 34% lower in the Met(+) cohort than in the Met(-) cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met(+) cohort than in the Met(-) cohort.
Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.
本研究旨在探讨二甲双胍对糖尿病患者头颈癌的影响。
我们比较了66600例患者，所有患者均患有糖尿病且均于2002年新诊断为头颈癌。其中一半患者接受二甲双胍治疗糖尿病（Met(+)），另一半未接受治疗（Met(-)：对照组）。所有患者在合并症（肥胖、冠状动脉疾病、高脂血症和高血压）、性别和年龄方面进行了匹配。确定了2011年底头颈癌的发病风险。
Met(+)队列中的头颈癌发病率比Met(-)队列低34%（调整后风险比[HR]=0.66；95%置信区间[CI]=0.55-0.79）。Met(+)队列中的口咽癌（调整后HR=0.66；95%CI=0.17-0.74）和鼻咽癌（NPC；调整后HR=0.50；95%CI=0.31-0.80）风险显著低于Met(-)队列。
二甲双胍与糖尿病患者发生头颈癌的较低风险相关。
